Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL DETERGENT VIRAL INACTIVATION PRODUCT INDUSTRY
2.1 Summary about Detergent Viral Inactivation Product Industry
2.2 Detergent Viral Inactivation Product Market Trends
2.2.1 Detergent Viral Inactivation Product Production & Consumption Trends
2.2.2 Detergent Viral Inactivation Product Demand Structure Trends
2.3 Detergent Viral Inactivation Product Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Kits and Reagents
4.2.2 Services
4.2.3 Viral Inactivation Systems and Accessories
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Blood & Blood Products
4.3.2 Cellular & Gene Therapy Products
4.3.3 Stem Cell Products
4.3.4 Tissue & Tissue Products
4.3.5 Vaccines and Therapeutics
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Kits and Reagents
5.2.2 Services
5.2.3 Viral Inactivation Systems and Accessories
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Blood & Blood Products
5.3.2 Cellular & Gene Therapy Products
5.3.3 Stem Cell Products
5.3.4 Tissue & Tissue Products
5.3.5 Vaccines and Therapeutics
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Kits and Reagents
6.2.2 Services
6.2.3 Viral Inactivation Systems and Accessories
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Blood & Blood Products
6.3.2 Cellular & Gene Therapy Products
6.3.3 Stem Cell Products
6.3.4 Tissue & Tissue Products
6.3.5 Vaccines and Therapeutics
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Kits and Reagents
7.2.2 Services
7.2.3 Viral Inactivation Systems and Accessories
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Blood & Blood Products
7.3.2 Cellular & Gene Therapy Products
7.3.3 Stem Cell Products
7.3.4 Tissue & Tissue Products
7.3.5 Vaccines and Therapeutics
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Kits and Reagents
8.2.2 Services
8.2.3 Viral Inactivation Systems and Accessories
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Blood & Blood Products
8.3.2 Cellular & Gene Therapy Products
8.3.3 Stem Cell Products
8.3.4 Tissue & Tissue Products
8.3.5 Vaccines and Therapeutics
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Kits and Reagents
9.2.2 Services
9.2.3 Viral Inactivation Systems and Accessories
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Blood & Blood Products
9.3.2 Cellular & Gene Therapy Products
9.3.3 Stem Cell Products
9.3.4 Tissue & Tissue Products
9.3.5 Vaccines and Therapeutics
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Clean Cells (France)
10.1.2 Charles River Laboratories International, Inc. (U.S.)
10.1.3 Danaher Corporation (U.S.)
10.1.4 Merck KGaA (Germany)
10.1.5 Parker Hannifin (U.S.)
10.1.6 Rad Source Technologies (U.S.)
10.1.7 Sartorius AG (Germany)
10.1.8 SGS S.A. (Switzerland)
10.1.9 Texcell, Inc. (France)
10.1.10 Viral Inactivated Plasma Systems SA (Switzerland)
10.1.11 WuXi PharmaTech (Cayman) Inc. (China)
10.2 Detergent Viral Inactivation Product Sales Date of Major Players (2017-2020e)
10.2.1 Clean Cells (France)
10.2.2 Charles River Laboratories International, Inc. (U.S.)
10.2.3 Danaher Corporation (U.S.)
10.2.4 Merck KGaA (Germany)
10.2.5 Parker Hannifin (U.S.)
10.2.6 Rad Source Technologies (U.S.)
10.2.7 Sartorius AG (Germany)
10.2.8 SGS S.A. (Switzerland)
10.2.9 Texcell, Inc. (France)
10.2.10 Viral Inactivated Plasma Systems SA (Switzerland)
10.2.11 WuXi PharmaTech (Cayman) Inc. (China)
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT